HealthEurope

Policy Spotlight

Red Alert for Women’s Hearts

Recommendations to improve the awareness, diagnosis and treatment of Cardio Vascular Diseases in women.

Summary Of ACCF/AHA 2009

Summary of ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults (JACC 2009; 54: 1364-1405) issued on September 29, 2009

EMEA Is Going To Be EMA, However This Is Not The Major Change Of The Identity Of The Agency

From 8 December 2009.

Focus on Science

Physician And Pharmacist Collaboration To Improve Blood Pressure Control

Studies have demonstrated that blood pressure control can be improved when clinical pharmacists assist with patient management.

Subclinical Atherosclerosis And Inflammatory Markers: The Influence On The Global CV Risk

There is great interest in identifying asymptomatic individuals at risk, who would be candidates for more intensive, evidence-based medical interventions aimed at preventing death and disability from coronary heart disease (CHD) and stroke.

Cardiovascular Risk Factors: A Continuing Evolution

The clinical approach to cardiovascular disease has changed dramatically in the past few decades. That is in part due to the increased knowledge of the epidemiology of related risk factors and to a larger availability of qualified biomarkers for the diagnosis, treatment, and prevention of the disease. Several papers appeared recently which focus on specific issues regarding the impact and explanation for these changes.

HealthEurope.org!

Women suffer for heart disease in term of prevalence of deaths and of disability more than men. In view of this, there is a clear case for EU to step up action to tackle heart disease and stroke in the two genders with particular attention to women.

Hot Topics

Further Lessons To Understand Better Statins And Cell-Dependent Effects In The Brain

Reports on the effectiveness of the use of statins in Alzheimer’s disease, though controversial, could encourage researchers to understand better the effects of statins on the brain, which are less well understood than their effects on other target organs, rather than justify a discontinuation of the research.